Get started

Financials · VRDN

Viridian Therapeutics Inc. (VRDN) financials

For the twelve months ended Sep 30, 2026, Viridian Therapeutics Inc. reported $26.31M of revenue and -$453.58M of net income.

Revenue, TTM
$26.31M
Revenue growth, YoY
-62.8%
Net income, TTM
-$453.58M
Net margin
-1724.1%
Free cash flow, TTM
-$343.44M
Cash
$172.86M
Total debt
$242.46M
P/S
122.97
Market cap
$3.24B
Annual revenue$70.85M
FY2016FY2025
Annual net income-$342.60M
FY2016FY2025
Annual free cash flow-$276.89M
FY2016FY2025

VRDN revenue and earnings growth

VRDN revenueQ3 2026$25.75M

Quarter YoY
-63.5%
QoQ
91x
FY YoY
235x
5Y CAGR
+132.2%
10Y CAGR
+39.5%

VRDN revenue was $25.75M in fiscal Q3 2026 (ended Sep 30, 2026), down 63.5% from a year earlier and up about 91-fold from the prior quarter. For the full fiscal 2025 it was $70.85M, up about 235-fold from fiscal 2024. Compound annual growth was +132.2% over 5 years and +39.5% over 10 years. It rose in 5 of the last 10 fiscal years. Fiscal 2025 is the highest of the 13 fiscal years on file.

VRDN net incomeQ3 2026-$101.21M

VRDN net income was -$101.21M in fiscal Q3 2026 (ended Sep 30, 2026), compared with -$34.60M a year earlier. For the full fiscal 2025 it was -$342.60M, compared with -$269.95M in fiscal 2024.

VRDN free cash flowQ3 2026-$93.14M

VRDN free cash flow was -$93.14M in fiscal Q3 2026 (ended Sep 30, 2026), compared with -$84.74M a year earlier. For the full fiscal 2025 it was -$276.89M, compared with -$232.83M in fiscal 2024.

Export CSV

Income statement

Income statement
Line item
FY2025
Dec 31, 2025
FY2024
Dec 31, 2024
FY2023
Dec 31, 2023
FY2022
Dec 31, 2022
FY2021
Dec 31, 2021
FY2020
Dec 31, 2020
FY2019
Dec 31, 2019
FY2018
Dec 31, 2018
FY2017
Dec 31, 2017
FY2016
Dec 31, 2016
Revenue$70.85M$302.0K$314.0K$1.77M$2.96M$1.05M$4.46M$8.39M$4.00M$3.48M
Cost of revenue---------$2.55M
Gross profit---------$929.0K
Research and development$338.93M$238.25M$159.76M$100.89M$56.89M$28.30M$34.79M$30.42M$19.62M$13.69M
Selling, general and admin$95.31M$61.08M$95.00M$35.18M$25.80M$13.27M$11.65M$11.05M$10.91M$6.77M
Operating income-$363.39M-$299.04M-$254.45M-$134.30M-$79.73M-$110.38M-$41.98M-$33.08M-$26.53M-$16.99M
Interest expense$4.95M$2.20M$1.33M$486.0K-----$95.0K
Income tax$0---------
Net income-$342.60M-$269.95M-$237.73M-$129.87M-$79.41M-$110.72M-$41.87M-$32.70M-$26.51M-$17.27M
EPS, basic---$5.31-$4.05-$6.66-$31.13-$20.04-$16.50-$20.70-$423.15
EPS, diluted---$5.31-$4.05-$6.66-$31.13-$20.04-$16.50-$20.70-$423.15
Diluted shares--44.8M32.1M11.9M3.6M2.1M2.0M1.3M40,934.467

Balance sheet

Balance sheet
Line item
FY2025
Dec 31, 2025
FY2024
Dec 31, 2024
FY2023
Dec 31, 2023
FY2022
Dec 31, 2022
FY2021
Dec 31, 2021
FY2020
Dec 31, 2020
FY2019
Dec 31, 2019
FY2018
Dec 31, 2018
FY2017
Dec 31, 2017
FY2016
Dec 31, 2016
Cash and equivalents$212.38M$99.59M$102.83M$155.58M$42.30M$45.90M$24.85M$32.61M$47.44M$22.10M
Short-term investments----$154.67M$81.74M$2.00M$29.88M$0-
Receivables$0-----$108.0K$24.0K$1.46M$20.0K
Inventory$0--------$64.0K
Current assets$894.23M$738.46M$486.48M$431.17M$200.16M$129.61M$29.74M$65.37M$51.87M$23.88M
Total assets$899.42M$742.40M$490.42M$435.09M$203.71M$131.25M$30.26M$66.15M$52.48M$24.76M
Current liabilities$70.70M$47.87M$26.64M$33.35M$13.64M$10.67M$10.18M$6.73M$3.90M$6.88M
Short-term debt-$0$0-------
Long-term debt$0$20.58M$20.20M-------
Total debt$0$20.58M$20.20M$4.64M$0-$8.30M$10.30M$9.92M$4.79M
Total liabilities$177.25M$70.76M$48.40M$40.03M$15.99M$11.22M$14.51M$14.80M$13.97M$9.71M
Shareholders' equity$722.17M$671.64M$442.02M$395.06M$187.72M$120.04M$15.75M$51.34M$38.51M-$61.92M

Cash flow

Cash flow
Line item
FY2025
Dec 31, 2025
FY2024
Dec 31, 2024
FY2023
Dec 31, 2023
FY2022
Dec 31, 2022
FY2021
Dec 31, 2021
FY2020
Dec 31, 2020
FY2019
Dec 31, 2019
FY2018
Dec 31, 2018
FY2017
Dec 31, 2017
FY2016
Dec 31, 2016
Operating cash flow-$276.39M-$232.32M-$184.17M-$93.84M-$54.58M-$29.78M-$36.06M-$26.84M-$28.17M-$14.76M
Capital expenditures$495.0K$511.0K$898.0K$797.0K$338.0K$42.0K$84.0K$445.0K$246.0K$250.0K
Free cash flow-$276.89M-$232.83M-$185.07M-$94.64M-$54.92M-$29.82M-$36.14M-$27.29M-$28.41M-$15.01M
Investing cash flow-$37.56M-$228.65M-$94.25M-$115.13M-$74.29M-$50.48M$28.23M-$29.91M$1.03M-$250.0K
Financing cash flow$426.74M$457.74M$225.67M$322.24M$125.28M$101.31M$70.0K$41.92M$52.47M$15.87M
Share repurchases---------$2.0K
Stock-based compensation$44.30M$42.15M$67.17M$19.77M$14.46M$3.65M$3.97M$3.68M$2.41M$198.0K
Depreciation and amortization$460.0K$540.0K$522.0K$255.0K$120.0K$239.0K$288.0K$281.0K$308.0K$341.0K

Key ratios

Key ratios
Line item
FY2025
Dec 31, 2025
FY2024
Dec 31, 2024
FY2023
Dec 31, 2023
FY2022
Dec 31, 2022
FY2021
Dec 31, 2021
FY2020
Dec 31, 2020
FY2019
Dec 31, 2019
FY2018
Dec 31, 2018
FY2017
Dec 31, 2017
FY2016
Dec 31, 2016
Revenue growth, YoY23359.9%-3.8%-82.3%-40.2%182.2%-76.5%-46.8%109.5%15.1%37.0%
Gross margin---------26.7%
Operating margin-512.9%-99018.2%-81035.0%-7579.2%-2690.8%-10512.4%-941.0%-394.5%-662.8%-488.6%
Net margin-483.6%-89387.1%-75711.5%-7329.2%-2680.2%-10544.3%-938.6%-390.0%-662.3%-496.8%
Free cash flow margin-390.8%-77096.0%-58938.9%-5340.6%-1853.5%-2840.1%-810.1%-325.4%-709.8%-431.6%
Return on equity-47.4%-40.2%-53.8%-32.9%-42.3%-92.2%-265.8%-63.7%-68.8%-
Return on assets-38.1%-36.4%-48.5%-29.8%-39.0%-84.4%-138.4%-49.4%-50.5%-69.8%
Current ratio12.6515.4318.2612.9314.6812.142.929.7113.313.47
Debt to equity0.000.030.050.010.00-0.530.200.26-

Source: XBRL data Viridian Therapeutics Inc. files with the SEC, latest filing dated Nov 4, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.

* Worked out from the filings rather than stated in them: Q4 is the full year less the first nine months.

Per-share figures and share counts are restated for stock splits the filings show: 1-for-13, first reported Mar 27, 2015; 1-for-15, first reported Mar 24, 2017; 1-for-15, first reported Mar 26, 2021.

EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.

VRDN peers

CompanyRevenueGrowthNet incomeNet marginMarket cap
VRDN$26.31M-62.8%-$453.58M-1724.1%$3.24B
LLY$86.46B+45.5%$27.58B31.9%$1.27T
JNJ$99.33B+7.8%$16.09B16.2%$664.95B
ABBV$66.01B+10.7%$10.34B15.7%$514.92B
MRK$67.38B+4.9%$2.45B3.6%$361.71B
NVS$54.53B+8.4%$13.98B25.6%$310.17B
AZN$58.74B+8.6%$10.22B17.4%$289.10B
ABT$48.23B+10.0%$4.70B9.7%$190.39B
NVODKK 309.06B+6.4%DKK 102.43B33.1%$178.51B

VRDN FAQ

7 questions
  • What is VRDN revenue?
    Viridian Therapeutics Inc. (VRDN) reported $26.31M of revenue for the twelve months ended Sep 30, 2026. That is down 62.8% from the year before. Revenue for fiscal 2025 was $70.85M.
  • Is VRDN profitable?
    No. Viridian Therapeutics Inc. reported a net loss of $453.58M for the twelve months ended Sep 30, 2026.
  • How much cash and debt does VRDN have?
    Viridian Therapeutics Inc. reported $172.86M in cash and cash equivalents and $242.46M of debt on its most recent balance sheet in SEC filings.
  • How fast is VRDN revenue growing?
    Viridian Therapeutics Inc.'s revenue changed 235x in fiscal 2025, to $70.85M. Its compound annual growth rate was +132.2% over 5 years and +39.5% over 10 years.
  • What is VRDN free cash flow?
    Viridian Therapeutics Inc. generated -$343.44M of free cash flow for the twelve months ended Sep 30, 2026, which is operating cash flow of -$341.50M less capital expenditures.
  • When did VRDN last report financial results?
    The latest statements here come from Viridian Therapeutics Inc.'s 10-Q filed on Nov 4, 2026, covering the period ended Sep 30, 2026.
  • Where does this VRDN financial data come from?
    Quantisnow builds these statements from the structured XBRL data Viridian Therapeutics Inc. files with the SEC. It is provided for information only and is not investment advice.